Back to results
US 2015/0306147 A1Published application
Isolated liver stem cells
AssigneeUniversité Catholique De Louvain
InventorsEtienne Sokal, Mustapha Najimi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversité Catholique De Louvain
InventorsEtienne Sokal, Mustapha Najimi
Estimating the term…
A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.
A method of treating liver-based inborn, metabolic deficiencies comprises administering human progenitor or stem cells, a cell population or progeny thereof to an individual in need thereof, wherein said human progenitor or stem cells, cell population or progeny thereof:
Dependencies are inferred from the claim text.